Key Points
- CEO Fred Aslan sold 3,187 shares on Dec. 15 at $6.00 each for $19,122, reducing his stake by 0.26% to 1,209,948 shares valued at about $7.26 million.
- Aslan has sold additional tranches recently (6,375 on Nov. 17 at $3.38 and 25,500 on Oct. 17 at $6.00), bringing his total recent sales to 35,062 shares for roughly $193,670.
- Artiva shares opened at $6.30 with a market cap of $154.6M and a 52‑week range of $1.47–$11.55, and analysts hold a consensus "Moderate Buy" with a $19.00 price target after the company slightly beat quarterly EPS estimates.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 3,187 shares of the firm's stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $6.00, for a total value of $19,122.00. Following the completion of the sale, the chief executive officer owned 1,209,948 shares of the company's stock, valued at approximately $7,259,688. This represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Fred Aslan also recently made the following trade(s):
- On Monday, November 17th, Fred Aslan sold 6,375 shares of Artiva Biotherapeutics stock. The stock was sold at an average price of $3.38, for a total value of $21,547.50.
- On Friday, October 17th, Fred Aslan sold 25,500 shares of Artiva Biotherapeutics stock. The stock was sold at an average price of $6.00, for a total value of $153,000.00.
Artiva Biotherapeutics Stock Performance
Shares of Artiva Biotherapeutics stock opened at $6.30 on Tuesday. The stock has a market capitalization of $154.63 million, a PE ratio of -2.44 and a beta of 3.10. Artiva Biotherapeutics, Inc. has a 52 week low of $1.47 and a 52 week high of $11.55. The stock has a 50 day moving average price of $3.70 and a two-hundred day moving average price of $2.91.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04. Research analysts forecast that Artiva Biotherapeutics, Inc. will post -4.95 EPS for the current year.
Institutional Investors Weigh In On Artiva Biotherapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC boosted its stake in shares of Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company's stock worth $2,291,000 after buying an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company's stock valued at $340,000 after acquiring an additional 117,733 shares during the last quarter. Marshall Wace LLP bought a new stake in Artiva Biotherapeutics during the second quarter worth $79,000. Nuveen LLC purchased a new position in Artiva Biotherapeutics in the first quarter worth $144,000. Finally, Jane Street Group LLC bought a new position in Artiva Biotherapeutics in the 2nd quarter valued at $67,000.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on ARTV shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a report on Thursday, October 30th. Wedbush lifted their price target on Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an "outperform" rating in a research note on Friday, October 17th. HC Wainwright boosted their price objective on Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a "buy" rating in a report on Wednesday, November 12th. Needham & Company LLC restated a "buy" rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a report on Friday, October 17th. Finally, Jefferies Financial Group raised Artiva Biotherapeutics to a "strong-buy" rating in a research report on Tuesday, November 18th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Artiva Biotherapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $19.00.
View Our Latest Report on Artiva Biotherapeutics
About Artiva Biotherapeutics
(
Get Free Report)
Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
